Document Type
Journal Article
Publication Date
6-2014
Journal
Diabetologia
Abstract
Aims/hypothesis
Skin fluorescence (SF) is a non-invasive marker of AGEs and is associated with the long-term complications of diabetes. SF increases with age and is also greater among individuals with diabetes. A familial correlation of SF suggests that genetics may play a role. We therefore performed parallel genome-wide association studies of SF in two cohorts.
Methods
Cohort 1 included 1,082 participants, 35–67 years of age with type 1 diabetes. Cohort 2 included 8,721 participants without diabetes, aged 18–90 years.
Results
rs1495741 was significantly associated with SF in Cohort 1 (p < 6 × 10−10), which is known to tag theNAT2 acetylator phenotype. The fast acetylator genotype was associated with lower SF, explaining up to 15% of the variance. In Cohort 2, the top signal associated with SF (p = 8.3 × 10−42) was rs4921914, also in NAT2, 440 bases upstream of rs1495741 (linkage disequilibrium r 2 = 1.0 for rs4921914 with rs1495741). We replicated these results in two additional cohorts, one with and one without type 1 diabetes. Finally, to understand which compounds are contributing to the NAT2–SF signal, we examined 11 compounds assayed from skin biopsies (n = 198): the fast acetylator genotype was associated with lower levels of the AGEs hydroimidazolones of glyoxal (p = 0.017).
Conclusions/interpretation
We identified a robust association between NAT2 and SF in people with and without diabetes. Our findings provide proof of principle that genetic variation contributes to interindividual SF and thatNAT2 acetylation status plays a major role.
Creative Commons License
This work is licensed under a Creative Commons Attribution 3.0 License.
APA Citation
Eny, K.M., Lutgers, H.L., Maynard, J., Klein, B.E.K., Lee, K.E. et al. (2014). GWAS identifies an NAT2 acetylator status tag single nucleotide polymorphism to be a major locus for skin fluorescence. Diabetologia.
Peer Reviewed
1
Open Access
1
ESM Study writing groups
ESM Table 1.pdf (179 kB)
ESM Table 1
ESM Table 2.pdf (167 kB)
ESM Table 2
ESM Table 3.pdf (174 kB)
ESM Table 3
ESM Table 4.pdf (102 kB)
ESM Table 4
ESM Table 5.pdf (87 kB)
ESM Table 5
ESM Table 6.pdf (219 kB)
ESM Table 6
ESM Table 7.pdf (210 kB)
ESM Table 7
ESM Table 8.pdf (100 kB)
ESM Table 8
ESM Table 9.pdf (155 kB)
ESM Table 9
ESM Table 10.pdf (96 kB)
ESM Table 10
ESM Fig. 1.pdf (384 kB)
ESM Fig. 1
ESM Fig. 2.pdf (26 kB)
ESM Fig. 2
ESM Fig. 3.pdf (258 kB)
ESM Fig. 3
ESM Fig. 4.pdf (785 kB)
ESM Fig. 4
ESM Fig. 5.pdf (785 kB)
ESM Fig. 5
ESM Fig. 6.pdf (120 kB)
ESM Fig. 6
ESM Fig. 7.pdf (861 kB)
ESM Fig. 7
ESM Fig. 8.pdf (284 kB)
ESM Fig. 8
Comments
Reproduced with permission of Springer, Diabetologia.